| 36.459 -1.201 (-3.19%) | 09-15 13:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 48.94  |
1-year : | 53.05 |
| Resists | First : | 41.9 |
Second : | 45.41 |
| Pivot price | 39.93 |
|||
| Supports | First : | 36.22 |
Second : | 30.13 |
| MAs | MA(5) : | 37.69 |
MA(20) : | 41.01 |
| MA(100) : | 36.27 |
MA(250) : | 28.73 |
|
| MACD | MACD : | -1 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 5.1 |
D(3) : | 5.4 |
| RSI | RSI(14): 30.1 |
|||
| 52-week | High : | 45.41 | Low : | 14.57 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IMVT ] has closed above bottom band by 12.7%. Bollinger Bands are 41.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 38.05 - 38.28 | 38.28 - 38.5 |
| Low: | 36.46 - 36.73 | 36.73 - 36.99 |
| Close: | 37.25 - 37.64 | 37.64 - 38.03 |
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Wed, 19 Aug 2026
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - Morningstar
Wed, 22 Jul 2026
Immunovant, Inc. ($IMVT) CEO 2026 Pay Revealed | IMVT Stock News - Quiver Quantitative
Thu, 02 Jul 2026
Chief Technology Officer Of Immunovant Sold 53% Of Their Shares - simplywall.st
Fri, 12 Jun 2026
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - Yahoo Finance
Thu, 28 May 2026
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating - Yahoo Finance
Tue, 26 May 2026
IMVT - Immunovant Inc Stock Price and Quote - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 207 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 56 (%) |
| Held by Institutions | 54 (%) |
| Shares Short | 16,980 (K) |
| Shares Short P.Month | 17,760 (K) |
| EPS | -2.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.8 % |
| Return on Equity (ttm) | -80.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -414 (M) |
| Levered Free Cash Flow | -239 (M) |
| PE Ratio | -13.03 |
| PEG Ratio | 0 |
| Price to Book value | 10.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|